<DOC>
	<DOCNO>NCT00672178</DOCNO>
	<brief_summary>The purpose study determine safety efficacy combine stereotactic body radiotherapy ( SBRT ) + sorafenib treatment patient Stage IV renal cell carcinoma ( RCC ) recur locally , develop progression unresectable primary progression extra-cranial and/or extra-pulmonary metastasis sorafenib . All subject remain sorafenib SBRT .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy ( SBRT ) Sorafenib Patients With Metastatic , Recurrent , Unresectable Renal Cell Cancer ( RCC )</brief_title>
	<detailed_description>In phase I portion investigation , subject enrol cohort three SBRT dose group . Subjects remain sorafenib therapy SBRT . Any change sorafenib dosage , SBRT discretion subject 's medical oncologist . Subjects assess , immediately 4 8 week post-therapy toxicity . Stereotactic body radiotherapy give increasingly high dose level cohort maximum tolerate dose radiation determine .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Age &gt; 18 year old Zubrod Performance Status 0 1 Adequate bone marrow , liver renal function assess follow : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 Total bilirubin &lt; 1.5 time institutional upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 time institutional ULN Creatinine &lt; 1.5 time institutional ULN Histologically cytologically confirm renal cell carcinoma , metastatic , unresectable recurrent . Life expectancy &gt; 6 month Local recurrence progression primary lesion progression , symptomatic progression extracranial , extrapulmonary metastasis sorafenib Measurable disease Bone metastases must tissue component measurable imaging . No untreated brain metastasis Resolution preexist toxicity prior therapy exclude alopecia taste alteration . Willingness ability comply continue sorafenib , visit , treatment plan , laboratory test study procedure . All treated lesion must comply SBRT dose constraint More 28 day since prior systemic local therapy cancer , include investigational agent surgical procedure exclusive sorafenib Women childbearing potential men must agree use adequate contraception ( barrier method birth control ) Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Ability understand willingness sign write informed consent . Prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit . Lesion remain ( solo ) kidney Contraindications radiotherapy prior radiotherapy overlap current site ( ) disease . Cardiac disease : Congestive heart failure . Patients must unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month . Cardiac ventricular arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management . Known human immunodeficiency virus ( HIV ) infection chronic Hepatitis B C. Active clinically serious infection Thrombolic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event within 4 week first dose study drug . Any hemorrhage/bleeding event within 4 week first dose study drug . Serious nonhealing wound , ulcer , bone fracture . Evidence history bleed problem Major surgery , open biopsy significant traumatic injury within 4 week first study drug . Use St. John 's Wort rifampin ( rifampicin ) . Known suspected allergy sorafenib agent give course trial . Any condition impair patient 's ability swallow whole pill . Any malabsorption problem .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>RCC</keyword>
	<keyword>metastatic</keyword>
	<keyword>sorafenib</keyword>
</DOC>